Three new cases are reported of cytogenetically Philadelphia-negative (Ph-) chronic myelocytic leukemia (CML), with positive BCR/ABL gene rearrangement according to a reverse transcriptase polymerase chain reaction technique. Fluorescence in situ hybridization (FISH) studies using different probes showed three different situations involving chromosomes 9 and 22 for the masked BCR/ABL fusion gene. With the use of BCR/ABL-extra signal and CEP 9 probes (Vysis, Downers Grove, IL, USA), FISH studies detected the BCR/ABL fusion gene at the end of chromosome 9 in patient 1, a BCR/ABL fusion gene on both chromosomes 22 in patient 2 (who was in an accelerated phase of CML), and a BCR/ABL fusion signal on chromosome 22 in patient 3. Interestingly, FISH interphase signals showed the same pattern in patients 1 and 3, but the BCR/ABL fusion gene was located on different chromosomes. Careful interpretation of the results and a simultaneous study of nuclei and metaphases are therefore recommended in each case. In conclusion, in cases of Ph- CML, FISH studies are of paramount importance since they can detect chromosomal reorganization and its location, and can also provide quantitative follow-up of these patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0165-4608(02)00662-3DOI Listing

Publication Analysis

Top Keywords

bcr/abl fusion
20
fusion gene
16
fish studies
12
bcr/abl gene
8
fluorescence situ
8
situ hybridization
8
three cases
8
chronic myelocytic
8
myelocytic leukemia
8
chromosome patient
8

Similar Publications

Vodobatinib is a Bcr-Abl 1 inhibitor, currently entering into Phase 2 clinical trials as a potential drug to treat glioblastoma patients. In the present work, a validated high-performance liquid chromatography (HPLC) detection method for the quantification of vodobatinib in rat plasma was established. Sample preparation involved liquid-liquid extraction method.

View Article and Find Full Text PDF

Overexpression of the myeloid Src-family kinases Fgr and Hck has been linked to the development of acute myeloid leukemia (AML). Here we characterized the contribution of active forms of these kinases to AML cell cytokine dependence, inhibitor sensitivity, and AML cell engraftment in vivo. The human TF-1 erythroleukemia cell line was used as a model system as it does not express endogenous Hck or Fgr.

View Article and Find Full Text PDF

[Acquisition of Primary Ph Bone Marrow Cells and Establishment of Ph B-ALL Mouse Model].

Zhongguo Shi Yan Xue Ye Xue Za Zhi

December 2024

Blood Disease Institute, Xuzhou Medical University,Xuzhou 221000, Jiangsu Province, China.

Article Synopsis
  • The objective of the study was to harvest primary Philadelphia chromosome-positive (Ph) cells from B-acute lymphoblastic leukemia (B-ALL) and create a B-ALL mouse model.
  • Methods included infecting bone marrow cells from C57BL/6J mice with a retrovirus, followed by the transplantation of transfected cells into irradiated mice, resulting in the establishment of multiple generations of Ph cells.
  • The results showed significant health deterioration in the mice post-transplant, with pathological features such as weight loss and leukemic cell infiltration in the liver, confirming the successful creation of a B-ALL mouse model through progressive passages of Ph cells.
View Article and Find Full Text PDF

Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance.

Malays J Pathol

December 2024

National Institutes of Health, Institute for Medical Research, Cancer Research Centre, Haematology Unit, 40170 Shah Alam, Selangor, Malaysia.

Introduction: The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs imatinib mesylate (IM) binding capacity, thus contributing to IM resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML) patients. Our study aims to determine the frequency of BCR::ABL1 KD mutations in CML patients with IM resistance.

View Article and Find Full Text PDF
Article Synopsis
  • Mirror-image proteins made from D-amino acids are promising for therapy due to their stability and minimal immune reactions.
  • Development involves creating D-target proteins, selecting L-binders via phage display, and synthesizing D-binders that interact with the natural L-targets.
  • The study focuses on D-monobodies with strong binding to the D-SH2 domain of the BCR::ABL1 kinase, showing potential for therapeutic applications by inhibiting its activity and functioning well in biological settings.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!